Vilaprisan (BioDeep_00000838028)

   


代谢物信息卡片


Vilaprisan

化学式: C27H29F5O4S (544.1706614)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C
InChI: InChI=1S/C27H29F5O4S/c1-24-14-21(15-3-7-18(8-4-15)37(2,35)36)23-19-10-6-17(33)13-16(19)5-9-20(23)22(24)11-12-25(24,34)26(28,29)27(30,31)32/h3-4,7-8,13,20-22,34H,5-6,9-12,14H2,1-2H3/t20-,21+,22-,24-,25-/m0/s1

描述信息

C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C1891 - Progesterone Antagonist
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent

同义名列表

1 个代谢物同义名

Vilaprisan



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Marcus-Hillert Schultze-Mosgau, Shunji Matsuki, Kazuhito Okumura, Masato Kaneko. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial. European journal of drug metabolism and pharmacokinetics. 2022 Jan; 47(1):49-56. doi: 10.1007/s13318-021-00727-8. [PMID: 34635989]
  • Marcus-Hillert Schultze-Mosgau, Andreas Kaiser, Frank S Zollmann. Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women. Clinical pharmacology in drug development. 2021 06; 10(6):675-680. doi: 10.1002/cpdd.876. [PMID: 33021044]
  • Hongzhong Liu, Ji Jiang, Zhaozhao Chen, Yunhui Zhang, Jinyi Li, Joachim Hoechel, Beate Rohde, Torsten Zimmermann, Marcus-Hillert Schultze-Mosgau. Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. Clinical pharmacology in drug development. 2021 05; 10(5):486-493. doi: 10.1002/cpdd.851. [PMID: 32716091]
  • Marcus-Hillert Schultze-Mosgau, Kenneth C Lasseter, Thomas Marbury, Stephanie Loewen, Kai Riecke. Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment. Journal of clinical pharmacology. 2020 08; 60(8):1030-1038. doi: 10.1002/jcph.1608. [PMID: 32227643]
  • Niladri Chattopadhyay, Kai Riecke, Sandra Ligges, Torsten Zimmermann, Atef Halabi, Marcus-Hillert Schultze-Mosgau. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study. British journal of clinical pharmacology. 2019 09; 85(9):2011-2021. doi: 10.1111/bcp.13992. [PMID: 31112623]
  • Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, Sebastian Frechen, Sandra Ligges, Torsten Zimmermann, Antje Rottmann, Bart Ploeger, Joachim Höchel, Marcus-Hillert Schultze-Mosgau. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. British journal of clinical pharmacology. 2018 12; 84(12):2857-2866. doi: 10.1111/bcp.13750. [PMID: 30171692]
  • Marcus-Hillert Schultze-Mosgau, Joachim Höchel, Olaf Prien, Torsten Zimmermann, Ashley Brooks, Jim Bush, Antje Rottmann. Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. Clinical pharmacokinetics. 2018 08; 57(8):1001-1015. doi: 10.1007/s40262-017-0607-4. [PMID: 29330782]
  • Barbara Schütt, Marcus-Hillert Schultze-Mosgau, Corinna Draeger, Xinying Chang, Stephanie Löwen, Andreas Kaiser, Beate Rohde. Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women. Journal of clinical pharmacology. 2018 02; 58(2):228-239. doi: 10.1002/jcph.998. [PMID: 28940451]
  • Barbara Schütt, Andreas Kaiser, Marcus-Hillert Schultze-Mosgau, Christian Seitz, David Bell, Manuela Koch, Beate Rohde. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Human reproduction (Oxford, England). 2016 08; 31(8):1703-12. doi: 10.1093/humrep/dew140. [PMID: 27288475]